{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:23:12Z","timestamp":1791400992410,"version":"4.3.3"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022854","name":"European Cystic Fibrosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.04.013","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:47:25Z","timestamp":1778125645000},"page":"584-593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ECFS statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2959-9964","authenticated-orcid":false,"given":"Kris","family":"De Boeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlou","family":"Bierlaagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5561-8893","authenticated-orcid":false,"given":"Kate","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-8630","authenticated-orcid":false,"given":"Margarida","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-3686","authenticated-orcid":false,"given":"Liron","family":"Birimberg-Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9190-8087","authenticated-orcid":false,"given":"John Joseph","family":"Brewington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-8871","authenticated-orcid":false,"given":"Bulent","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-9789","authenticated-orcid":false,"given":"Martin","family":"Mense","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-1720","authenticated-orcid":false,"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Tayor-Cousar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.04.013_bib0001","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biocel.2014.02.023","article-title":"Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies","volume":"52","author":"Fanen","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2026.04.013_bib0002","article-title":"CFTR gene variants, epidemiology and molecular pathology","volume":"27","author":"Bareil","year":"2020","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.jcf.2026.04.013_bib0003","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/thx.2005.043539","article-title":"Cystic fibrosis: terminology and diagnostic algorithms","volume":"61","author":"De Boeck","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2026.04.013_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","author":"Burgel","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0005","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41467-022-28343-3","article-title":"Whole exome sequencing in Alopecia Areata identifies rare variants in KRT82","volume":"13","author":"Erjavec","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2026.04.013_bib0006","series-title":"ECFSPR Annual Report 2022","author":"Zolin","year":"2024"},{"key":"10.1016\/j.jcf.2026.04.013_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13073-017-0403-7","article-title":"Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation","volume":"9","author":"Kobayashi","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0008","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00439-020-02135-5","article-title":"Determining the incidence of rare diseases","volume":"139","author":"Bainbridge","year":"2020","journal-title":"Hum Genet"},{"key":"10.1016\/j.jcf.2026.04.013_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"Chowdhury BA. The U.S. food and drug administration's experience with ivacaftor in cystic fibrosis. establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.04.013_bib0010","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1126\/science.aaw0553","article-title":"Making precision medicine personal for cystic fibrosis","volume":"365","author":"Manfredi","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jcf.2026.04.013_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14113978","article-title":"Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: a review of registry-based evidence","volume":"14","author":"Salvatore","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0012","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/molecules29040821","article-title":"Organic synthesis and current understanding of the mechanisms of CFTR modulator drugs ivacaftor, tezacaftor, and elexacaftor","volume":"29","author":"Ferreira","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.jcf.2026.04.013_bib0013","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01959-2023","article-title":"Gathering real-world compassionate data to expand eligibility for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint","volume":"63","author":"Burgel","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.04.013_bib0016","doi-asserted-by":"crossref","first-page":"802-7.e1-3","DOI":"10.1016\/j.jpeds.2010.05.018","article-title":"Cutting GR. Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function","volume":"157","author":"Collaco","year":"2010","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2026.04.013_bib0017","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jcf.2019.10.022","article-title":"Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations","volume":"19","author":"de Winter-de Groot","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0018","first-page":"61","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.04.013_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103476","article-title":"Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programme","author":"Burgel","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcf.2026.04.013_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001153","article-title":"Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier","volume":"6","author":"Hinzpeter","year":"2010","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jcf.2026.04.013_bib0021","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcf.2024.09.013","article-title":"Theranostics vs theratyping or theranostics plus theratyping?","volume":"24","author":"Amaral","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0022","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcf.2024.09.019","article-title":"Elexacaftor\/tezacaftor\/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls","volume":"24","author":"Kroes","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0023","article-title":"Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium","volume":"266","author":"Sheppard","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0024","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1074\/jbc.M116.764720","article-title":"Correctors and potentiators rescue function of the truncated W1282X-cystic fibrosis transmembrane regulator (CFTR) translation product","volume":"292","author":"Haggie","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2026.04.013_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0026","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0027","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jcf.2023.04.003","article-title":"Targeted locus amplification reveals heterogeneity between and within CFTR genotypes and association with CFTR function in patient-derived intestinal organoids","volume":"22","author":"Lefferts","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0028","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/cts.12927","article-title":"G970R-CFTR mutation (c.2908G>C) results predominantly in a splicing defect","volume":"14","author":"Fidler","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jcf.2026.04.013_bib0029","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0030","article-title":"van der Ent CK, ten Ham RMT. Early economic evaluation of a predictive tool to test CFTR modulator treatment response in people with cystic fibrosis [Preprint]","author":"de Groot","year":"2026","journal-title":"medRxiv"},{"key":"10.1016\/j.jcf.2026.04.013_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del complex allele hampers pharmacological rescue of mutant CFTR by elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis patients: the value of the ex vivo nasal epithelial model to address non-responders to CFTR -modulating drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.04.013_bib0032","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jcf.2024.04.016","article-title":"Centralized intestinal organoid generation is a feasible and safe approach for personalized medicine as demonstrated in the HIT-CF Europe Organoid Study","volume":"23","author":"Bierlaagh","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0033","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00109-017-1531-7","article-title":"Stem cell-derived organoids and their application for medical research and patient treatment","volume":"95","author":"Bartfeld","year":"2017","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.jcf.2026.04.013_bib0034","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2026.04.013_bib0035","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1126\/science.1234852","article-title":"Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications","volume":"340","author":"Sato","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jcf.2026.04.013_bib0036","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0037","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jcf.2023.03.004","article-title":"FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes","volume":"22","author":"de Poel","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0038","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00495-2022","article-title":"High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing","volume":"9","author":"Spelier","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2026.04.013_bib0039","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00770-2023","article-title":"Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: a personalised approach","volume":"63","author":"Spelier","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.04.013_bib0040","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/thoraxjnl-2020-216368","article-title":"Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis","volume":"76","author":"Cuyx","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2026.04.013_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914539","article-title":"CFTR function restoration upon elexacaftor\/tezacaftor\/ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.04.013_bib0042","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0043","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.04.013_sbref0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.01.019","article-title":"CRISPR-based adenine editors correct nonsense mutations in a cystic fibrosis organoid biobank","volume":"26","author":"Geurts","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcf.2026.04.013_bib0045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcf.2026.04.013_bib0046","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02529-2017","article-title":"Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function","volume":"52","author":"de Winter-de Groot","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.04.013_bib0047","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00508-2021","article-title":"Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression","volume":"60","author":"Muilwijk","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.04.013_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100019","article-title":"Protocol for application, standardization and validation of the forskolin-induced swelling assay in cystic fibrosis human colon organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"STAR Protoc"},{"key":"10.1016\/j.jcf.2026.04.013_bib0049","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jcf.2024.04.014","article-title":"Repeatability and reproducibility of the Forskolin-induced swelling (FIS) assay on intestinal organoids from people with Cystic Fibrosis","volume":"23","author":"Bierlaagh","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0051","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1164\/rccm.202004-1200LE","article-title":"Comparison of organoid swelling and in vivo biomarkers of CFTR function to determine effects of lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation","volume":"202","author":"Graeber","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0052","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0053","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.04.013_sbref0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcf.2026.04.013_bib0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12931-017-0706-7","article-title":"Characterization of pediatric cystic fibrosis airway epithelial cell cultures at the air-liquid interface obtained by non-invasive nasal cytology brush sampling","volume":"18","author":"Sch\u00f6gler","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.jcf.2026.04.013_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101419","article-title":"Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants","volume":"3","author":"Golec","year":"2022","journal-title":"STAR Protoc"},{"key":"10.1016\/j.jcf.2026.04.013_bib0057","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1113\/JP282143","article-title":"Correlating genotype with phenotype using CFTR-mediated whole-cell Cl(-) currents in human nasal epithelial cells","volume":"600","author":"Noel","year":"2022","journal-title":"J Physiol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0058","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.04.013_bib0059","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99385","article-title":"Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies","volume":"3","author":"Brewington","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2026.04.013_bib0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00018-022-04215-3","article-title":"Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor\/tezacaftor\/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants","volume":"79","author":"Borgo","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcf.2026.04.013_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1494327","article-title":"Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators","volume":"15","author":"Tomati","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0062","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050421","article-title":"Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids","volume":"11","author":"Silva","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0063","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1165\/rcmb.2021-0337OC","article-title":"Molecular dynamics and theratyping in airway and gut organoids reveal R352Q-CFTR conductance defect","volume":"67","author":"Wong","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0064","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201857","article-title":"Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis","volume":"6","author":"Birimberg-Schwartz","year":"2023","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.jcf.2026.04.013_bib0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1164\/rccm.201808-1436LE","article-title":"Might brushed nasal cells be a surrogate for CFTR modulator clinical response?","volume":"199","author":"Pranke","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1651122","article-title":"Nasal cells as a bronchial cell surrogate for pre-clinical assessment of drug response in cystic fibrosis","volume":"16","author":"Barillaro","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0067","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3389\/fped.2020.00536","article-title":"Functional profiling of CFTR-directed therapeutics using pediatric patient-derived nasal epithelial cell models","volume":"8","author":"Park","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jcf.2026.04.013_bib0068","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01855-2024","article-title":"Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis","volume":"65","author":"Ratjen","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.04.013_bib0069","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00778-2025","article-title":"Theratyping in cystic fibrosis: filling the knowledge gaps","volume":"65","author":"Pranke","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.04.013_bib0070","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bbadis.2019.01.029","article-title":"Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del\/F508del Cystic Fibrosis patients","volume":"1865","author":"Kmit","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jcf.2026.04.013_bib0071","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076576","article-title":"Clinical consequences and functional impact of the rare S737F CFTR variant and its responsiveness to CFTR modulators","volume":"24","author":"Terlizzi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.04.013_bib0072","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.04.013_bib0073","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","volume":"23","author":"Bihler","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.04.013_bib0074","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1165\/rcmb.2008-0018OC","article-title":"Functional properties of mixed cystic fibrosis and normal bronchial epithelial cell cultures","volume":"40","author":"Dannhoffer","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0075","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00049.2005","article-title":"Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR","volume":"289","author":"Farmen","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0076","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1165\/rcmb.2001-0004OC","article-title":"Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis","volume":"27","author":"Ramalho","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0077","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0078","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202101320","article-title":"Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia","volume":"5","author":"Amatngalim","year":"2022","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.jcf.2026.04.013_bib0079","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jcmgh.2017.11.013","article-title":"Cftr modulates Wnt\/\u03b2-catenin signaling and stem cell proliferation in Murine intestine","volume":"5","author":"Strubberg","year":"2018","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.04.013_bib0080","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/sctm.20-0453","article-title":"High density bioprocessing of human pluripotent stem cells by metabolic control and in silico modeling","volume":"10","author":"Manstein","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcf.2026.04.013_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101394","article-title":"GMP-compatible manufacturing of three iPS cell lines from human peripheral blood","volume":"35","author":"Haase","year":"2019","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.jcf.2026.04.013_bib0082","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.stemcr.2019.04.014","article-title":"High-throughput screening for modulators of CFTR activity based on genetically engineered cystic fibrosis disease-specific iPSCs","volume":"12","author":"Merkert","year":"2019","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.jcf.2026.04.013_bib0083","doi-asserted-by":"crossref","DOI":"10.3791\/63882","article-title":"Generation of airway epithelial cell air-liquid interface cultures from human pluripotent stem cells","author":"Berical","year":"2022","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jcf.2026.04.013_bib0084","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s13287-025-04737-0","article-title":"Human induced pluripotent stem cells for in vitro modeling of impaired mucociliary clearance in cystic fibrosis lung disease","volume":"16","author":"Klassen","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcf.2026.04.013_bib0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcf.2023.10.010","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis","volume":"23","author":"Donaldson","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326001050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326001050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:08:36Z","timestamp":1785528516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1569199326001050"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.04.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ECFS statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}